StudyofDWIpredictingtheefficacyofneoadjuvantchemotherapyindifferentmolecularsubtypesofbreastcancer / 实用放射学杂志

ABSTRACT

Objective ToinvestigatethevalueoftheADCandtherelativeADC(rADC)ofDWIparameterstopredictthefinal pathologicalresponseintheearlystageofneoadjuvantchemotherapy(NAC)fordifferentmolecularsubtypesofbreastcancer.Methods TheresultsoftwoDWI(beforeNACandwithinoneweekaftersecondcycleofNAC)in116patientsenrolledinthestudywere retrospectivelyanalyzed.Theminimum ADCandrADCofthelesionsweremeasuredandrecorded,andtheirratesofchangeaftersecond cycle(ADC%、rADC%)werecalculated.Molecularsubtypeswererecordedaccordingtotheresultsofpreoperativeimmunohistochemistry, andpatientsweredividedintomajorhistologicalresponse(MHR)groupandnon-majorhistologicalresponse(NMHR)groupaccording topostoperativepathologicalgradingcriteriaofMiller&Payne.Results TherewasnocorrelationbetweentheADCbeforeNACand thefinalpathologicalresponseofeachsubtype.AftersecondcycleofNAC,exceptforLuminalA,ADCandADC%hadtheabilityof predictingfinalpathologicalresponsesfortheremainingsubtypes,especiallyinthehighestefficacyofADC%forthetriple-negative. BeforeNAC,rADChadpredictiveefficacyforLuminlBandHER2-enrichedsubtypes;aftersecondcycleofNAC,therADCdiffered onlybetweenthedifferentpathologicalresponsegroupsofHER2-enrichedandthetriple-negative,andthediagnosticefficacy was limited.TherADC%hadpredictiveefficacyonlyinthetriple-negativegroup.Conclusion ADChasnopredictiveefficacyforeach subtypebeforeNAC;WhiletherADCbeforeNAC,everyDWIparametersafter2ndcycleofNAC,andtheirchangeshavecertainvalues toevaluatethefinalpathologicalresponseofthecorrespondingpartialsubtypesofbreastcancer.